News - idelalisib, Genito-urinary

Filter

Current filters:

idelalisibGenito-urinary

Popular Filters

1 to 25 of 43 results

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11-04-2014

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

BiotechnologyEuropeGilead SciencesidelalisibImbruvicaJohnson & JohnsonMarkets & MarketingOncologyUSA

India’s IPAB upholds Pfizer’s Detrol patent

India’s IPAB upholds Pfizer’s Detrol patent

27-03-2014

In a positive development for US drug giant Pfizer, India's Intellectual Property Appellate Board (IPAB)…

Asia-PacificDetrolGenito-urinaryIndiaPatentsPfizerPharmaceuticalRanbaxy Laboratories

Idelalisib may represent promising treatment for stubborn blood cancers

11-03-2014

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma…

BiotechnologyGilead SciencesHematologyidelalisibOncologyResearch

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

24-01-2014

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing…

BiotechnologyGilead SciencesidelalisibOncologyResearch

Teva launches authorized generic of Detrol in USA

Teva launches authorized generic of Detrol in USA

04-01-2014

Israel’s Teva Pharmaceutical Industries, the world’s largest generic drugmaker, says it has launched…

Detrol LAGenericsGenito-urinaryMarkets & MarketingNorth AmericaPfizerTeva Pharmaceutical IndustriesUSA

Positive top-line Ph III results with ceftolozane/tazobactam in cUTI

25-11-2013

US biopharma company Cubist Pharmaceuticals has revealed positive top-line results from its pivotal Phase…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsGenito-urinaryPharmaceuticalResearchtazobactam

Gilead to stop Ph III Study 116 of idelalisib early on DMC recommendation

10-10-2013

Following a recommendation by an independent Data Monitoring Committee, US HIV/AIDS drug major Gilead…

BiotechnologyGilead SciencesidelalisibOncologyResearch

SOBI gains rights to distribute Ravicti in Middle East

01-10-2013

Swedish Orphan Biovitrum says Hyperion Therapeutics has granted it exclusive rights to distribute its…

Genito-urinaryHyperion TherapeuticsLicensingPharmaceuticalRavictiRest of the WorldSobiSwedish Orphan Biovitrum

Gilead files for US approval of iNHL drug candidate

12-09-2013

US biotech major Gilead Sciences (Nasdaq: GILD), best known for its prowess in antivirals (HIV and hepatitis…

BiotechnologyGilead SciencesidelalisibNorth AmericaOncologyRegulation

UK MHRA licenses Allergan's Botox for use in patients with overactive bladder

11-09-2013

Botox (botulinum toxin type A), from US drugmaker Allergan (NYSE: AGN), has been licensed by the UK Medicines…

AllerganBotoxEuropeGenito-urinaryPharmaceuticalRegulation

Positive Ph II results for Gilead's idelalisib in refractory indolent non-Hodgkin's lymphoma

17-06-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) today (June 17) announced encouraging interim results…

BiotechnologyGilead SciencesidelalisibOncologyResearch

Netherlands first to approve Astellas' Vesomni

23-05-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says that the Dutch Medicines…

Astellas PharmaEuropeGenito-urinaryPharmaceuticalRegulationVesomni

NovaBay Pharmaceuticals: tuning in for a crescendo of data, say analysts

13-05-2013

US biotech firm NovaBay Pharmaceutical's (Nasdaq: NBY) first-quarter 2013 results set the scene for a…

Antibiotics and Infectious diseasesauricloseneBiotechnologyFinancialGenito-urinaryNovaBay PharmaceuticalNVC-422OphthalmicsResearch

Drais Pharma to develop third Astellas compound through Tacurion

08-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based Drais Pharmaceuticals have entered into…

ASP7035Astellas PharmaDrais PharmaceutialsGenito-urinaryLicensingPharmaceuticalResearchTacurion

Auxilium Pharma acquires Actient in $585 million deal

29-04-2013

Specialty drugmaker Auxilium Pharmaceuticals (Nasdaq: AUXL) says that it has completed the acquisition…

Actient PharmaAuxilium PharmaceuticalsGenito-urinaryMen's HealthMergers & AcquisitionsPharmaceutical

Positive data expected for RedHill Biopharma's Crohn's disease candidate

22-04-2013

Analysts at Roth Capital Partners have launched coverage of Israel-based specialty pharma company RedHill…

FinancialGenito-urinaryPharmaceuticalRBH-104RedHill BiopharmaResearch

Lilly's ED drug Cialis meets endpoint in LUTS/BPH study

19-03-2013

US drug major Eli Lilly (NYSE: LLY) presented results yester day at the annual European Association of…

CialisEli LillyGenito-urinaryMen's HealthPharmaceuticalResearch

Dainippon Sumitomo partners with Nippon Shinyaku for urology drug AMP-986

12-03-2013

Japanese drugmakers Dainippon Sumitomo Pharma (TYO: 4506) and Nippon Shinyaku (TYO: 4516) have concluded…

AMP-986Asia-PacificDainippon Sumitomo PharmaGenito-urinaryLicensingNippon ShinyakuPharmaceutical

Research results for Pfizer's Chantix, Pristiq and Toviaz

27-01-2013

Global drugs behemoth Pfizer (NYSE: PFE) last week released a batch of new clinical trial data relating…

ChantixGenito-urinaryNeurologicalPfizerPharmaceuticalPristiqResearchToviaz

FDA approves Allergan's Botox for OAB and NuPathe's Zecuity for migraine

21-01-2013

US drugmaker Allergan (NYSE: AGN) says that the US Food and Drug Administration has approved its Botox…

AllerganBotoxGenito-urinaryNeurologicalNorth AmericaNuPathePharmaceuticalRegulationZecuity

Astellas' Betmiga Oked in EU for overactive bladder

14-01-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has received approval from…

Astellas PharmaBetmigaEuropeGenito-urinarymirabegronPharmaceuticalRegulation

1 to 25 of 43 results

Back to top